Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid ...

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Among patients with diabetes receiving PCI, novel antidiabetic agents may reduce risk for acute kidney injury.

DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR (“TGFR”) system received FDA ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Chronic Kidney Disease (CKD) affects approximately 15% of U.S. adults and as many as 9 in 10 with CKD are unaware they have ...

Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.

First-ever positive profit, entering a new era of growth and global innovation ...